Christoffer Søderberg
Investitore di Private Equity presso Novo Principal Investments
Profilo
Christoffer Søderberg is currently a Senior Partner at Novo Principal Investments since 2019.
Previously, he worked as a Director at Symphogen A.
He completed his undergraduate and graduate degrees at Copenhagen Business School.
Posizioni attive di Christoffer Søderberg
| Società | Posizione | Inizio |
|---|---|---|
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investitore di Private Equity | 01/02/2016 |
Precedenti posizioni note di Christoffer Søderberg
| Società | Posizione | Fine |
|---|---|---|
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Direttore/Membro del Consiglio | 03/09/2018 |
Formazione di Christoffer Søderberg
| Copenhagen Business School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
- Borsa valori
- Insiders
- Christoffer Søderberg
